Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Very simple, regular (loyal) CBD consumers will find the cheapest and most simple way to get their dose. But good luck with your dream...just make sure to follow the cash flow of any new company very closely. It always goes positive before a positive EPS shows up in the radar. Sometimes 3 to 5 quarters before.
On the other hand, historically when JD starts paying up debt (and in full) it's because better things are coming for the stock. It's confusing because the growth trend is obviously going in the wrong direction so my bet is M&A in the works. A lot of that is happening at these historic low prices everywhere in the market.
The other more remote possibility is that JD has a couple of new deals lined up now that California is opening up to CBD. That would be the best case scenario I think. Maybe a follow up PR is coming soon.
I wish you all good luck either way..
PS. I don't like the 20% discount on the total amount. Seems abusive but at the same time is very normal in this special situations.
JMHO
It just sounds like too complicated ! Why try to mix oil and water ?
If you need water take it. It you need or want your CBD, then take it too with much simpler formats. IDK it's just my honest opinion. I have been taking CDB for 4 years, oil & sublingual because that's what works for me. It's becoming cheaper every year but always PlusCBD Gold & Green and I wish they had the Raw still which works great for sore bones and muscles. But all in oil spray sublingual. Almost all my family uses it so I know the compound works. And it's a fundamental part of my diet.
Sleep well and function even better all day..and that's what matters.
Until some new Nano-Tech format start showing up with better results I will keep using what I know works for me and then I will switch for sure because it will be more effective and cheaper. As simple as that.
Good luck to all CBD investors !!!
Light and air degrade CBD
CBD is a highly unstable compound that requires careful preparation and storage to help preserve its medicinal properties.
In particular, exposure to light and air can cause it to break down, negating its potential beneficial effects.
Most CBD water is stored on grocery shelves under bright lights in clear containers for days or even weeks, degrading its CBD content.
One study evaluated the effects of certain storage conditions on cannabinoids and found that exposure to light caused the greatest loss of CBD (7Trusted Source).
Temperature had no effect, but exposure to air also led to significant losses in cannabinoid content. Therefore, as soon as you open CBD water, the little CBD it contains immediately begins to break down (7Trusted Source).
Although more studies are needed, these findings suggest that CBD water is unlikely to have much of a medicinal impact.
SUMMARY
Light and air can cause CBD to break down, negating its potential health benefits. CBD water is often sold in clear bottles, so the CBD inside may have already broken down significantly by the time you drink it.
CBD water is expensive
If you’re looking to try CBD, drinking CBD water is one of the most expensive routes to take.
A single 16-ounce (473-ml) serving can cost around $4–7 USD, excluding tax and shipping.
Buying in bulk can help you save money, but each bottle still comes out to at least $3 USD.
For example, CBD oil typically costs around $35–40 for about 30 servings, which equates to less than $2 per serving.
This is significantly more pricey than other forms of CBD.
CBD capsules, gummies, vapes, and creams can also provide a good amount of CBD for a lower cost per serving.
SUMMARY
CBD water is more expensive than other forms of CBD, including capsules, gummies, vapes, and creams.
Written by Rachael Link, MS, RD on June 6, 2019
3 years old !!!
No CBD investment will work until fully or partially regulated. The FDA is to blame for this. 3 and 1/2 years and counting since December 26, 2018. It's very hard to believe but it's happening.
Just running any normal (& successful) business has it's many complications but without regulations it's simply impossible.
I just hope that the FDA is forced to do something positive and soon.
Check The Valens Company (VLNS with better revs) or Lexaria (LEXX with worst) if you want to have an idea of what happens when you uplist to the nasdaq by RSS wihtout having a solid revenue growth story and operational growth stability. You need to be able to demonstrate that the business will turn a penny of profits within few quarters these days if you want to be considered a winner. And reasonable cash available or ways to finance the operation before any attempt to join the Nasdaq.
The trend @ CVSI must change in a convincing way for the share price to improve above 50 cents before attempting any 4 to 7X RSS. It is just impossible at this SP level if you need a $2.00 sustainable SP to uplist.
From what I have seen in the last couple of years every single company uplisting via RSS drops after joining the Nasdaq for a while at least. It's a very interesting phenomenon or more like an opportunity for the savvy when the companies are good ones.
Make a list of RSS uplisting companies in the past few years and study the trends to understand it.
What was Jetty Extracts forward revenue estimate at the moment or revenue growth history ?
Thanks !
Wasn't CVSI the first company to conduct it's own CBD/Liver studies ???
Hello to the board !
It seems like the "Excise Tax" ate away over 21% of the gross revenue ! Does anybody knows the limit to this tax ??? Wasn't it 18% or close to this ?
If Valens wants to reach $225M in NET revenues by 2023, then the revenues should experience explosive upsides starting on Q2 this year which is reported on mid July (Q1 by mid April). It should NOT be less than $30-32M gross revenue according to my estimates. And the YoY growth for FY2023 should be bigger than the FY2022. Explosive growth of 80% YoY for 2023. And 65 to 70% this year.
I can't see it !
Holly $&%()$T !!!
Key questions:
Does the management team has enough visibility to see this kind of growth ?
Is it possible with all the recent acquisitions ?
Will the B2B segment contribute a good percentage, say 15 to 20%.
They are assigning a 35 to 40 % of total revenue to CBD this year. Coming form Green Roads. Are all these new international contracts worth that much growth ? On top of the new brand initiatives for e-commerce ? Or is this coming from Big Chain Retailers like other CBD company are signing new deals.. Like GNC and others ? This could be possible
The biggest contributor should be the provincial listings.
Quebec is NOT included in their estimates as per Everett K in the conference call:
Everett Knight
"36:08 Yes. Thank you, Andrew. It's Everett here. I'd say we're just in the beginning innings of that strategy taking fruition. To be clear, actually, in the guidance we put out in our objectives, that does not include Quebec today. So all of those benchmarks that investors should be guiding us to and executing on doesn't include it, I would say that's upside. We're going to give more information on that throughout the year, and we'll give more transparency as it comes to fruition."
------------------------
So the Q2 financials should a huge indicator of what's coming.
Plenty of great information out today. It will take me a couple of days to digest all of these new material but it was a very complete presentations. I hope they do this every year at least.
They key here is to go VERY long and not worry about the day to day. These kids are very smart and they will find their way to the top.
And the stock price tRight now is ideal to star a position.
GLTA
Just impressive, thanks Sleuth
Apparently we won't see much until mid July when the Q2'22 results are released..
6 more months. I guess is NOT much after a very LONG wait.
Things I liked about the PR:
“It’s a pivotal time for Valens after a very acquisitive 2021 that saw us accelerate our business plan from three years to one and create a leading cannabis consumer products company with an exciting portfolio of brands,” said Tyler Robson, Chief Executive Officer and Chairman of The Valens Company.
This shows creativeness, smarts and execution capacity while under adverse market conditions. Very impressive how the manage to do all that in such a short period of time.
$20M in cost savings per year (Total) is quite a big chunk of whatever costs rate we will have this year. Gross margins should and need to look a LOT better for the stock to become attractive.
We will have a better picture after the Investors day but so far we are burning cash in operations at a rate above $40M per year.
The annual "Cost of Sales" will be around $60M and the OPEX will also be above $60M.
“As we redirect our focus to realizing the full package of targeted benefits from these acquisitions, we are now capturing the first wave of synergies through operational and organizational changes that we believe will not only improve our efficiencies but also drive the business towards becoming EBITDA positive in fiscal Q4 2022, which will be discussed in greater detail on our upcoming investor day."
I can't see this (EBITDA positive by Q4) yet but I hope I will. They should at least get close to that objective but right now it looks more like a FY2023 thing if possible.
"I’m proud to say that we have identified $10 million in annual cost efficiencies and expect to identify an additional $10 million in the coming quarters through additional planned initiatives. Investors can expect to start to see some of the benefits of the first wave of efficiencies in fiscal Q2 2022, with the majority of the impact being realized in the second half of the fiscal year.”
Overall, I like what I am reading so far. I need more numbers to have a clear pictures which will come with the next couple of financial results releases.
Short and sweet explanation. Just great, thanks..
I have search for this fact and I haven't been able to find it. From looking at the financials I found that very hard. I can see (JMHO) a spike in sales of 25-35% coming this year from different marketing initiatives (new products) and other regulatory and scientific news over the past 12 months but the operating cash flow won't be positive. Maybe in 2023.
If you have a source, please post it.
And I also see that the operating expenses are improving too but the company needs to ramp up the volume in sales to achieve better gross and operating margins.
Amen, and Amen
PlusCBD discontinued de Raw formula in the oil drops/spray format a while back. I think that they only have it in the soft gel format. I was taking it (along with the Gold) and giving it to my kids too. I imagine it was due to the lack of interest (generalized ignorance about it's properties) and now is a wonder product.
I hope they reactive it's production ASAP. And in gummies format too.
We should all try and send the message to management to reactivate the RAW segment in all formats.
GLTA and it looks like things are starting to turn around, slowly but surely.
Always following and keeping track. Back on board soon.
https://www.thecbdistillery.com/product/raw-synergy-cbda-cbd-1-1-tincture-1000mg-30ml/?&promo=CBDAINSIDER&irclickid=Rb4zzqypfxyIT-jUfoV-HRbBUkG3bKz3dQgAS00&irgwc=1&utm_source=impact&Partner=The%20CBD%20Insider&impactmediapartner=1721033
"Raw Synergy CBDA + CBD 1:1 Tincture Oil offers all the wellness benefits of Full Spectrum CBD, plus CBDA (Cannabidiolic Acid). This CBDA + CBD oil tincture is formulated with a robust terpene profile unique to raw CBD extracts. Consider this tincture as fresh-squeezed juice. CBDA is the rawest form of CBD on the market. Each bottle contains 500mg of CBDA and 500mg of CBD. Experience a boost in the Entourage Effect when CBDA binds with your Endocannabinoid System (ECS) and receive enhanced health and wellness benefits with Raw Synergy CBDA + CBD Tincture Oil from CBDistillery®.
Notice: Due to high demand, the CBDA + CBD Raw Synergy Tincture is currently on backorder and will ship the week of February 7th. The rest of your order will ship as normal.
............................
Its seems like we are missing out now in this segment....
Analysts 12-Month Price Target
Average 11.75 (+264.91% Upside)
https://ca.investing.com/equities/valens-groworks-consensus-estimates
In CAD
And when they join the NAS there will be more pain as all companies are trashed the first 4 to 6 weeks to weed out the weak hands and old frustrated Longs. Fresh and savvy Nasdaq investors with deep pockets will get together and collapse the SP as much as they can before letting it run. So get some cash for when it comes back to $3.05 - 25 or even $2.75 after the Nasdaq Uplisting.. That's my plan
I hope they join the Nasdaq before January.
It seems like we found the bottom yesterday @ $3.06
I was expecting a drop and I should had waited for that. Didn't time it correctly. Went All-In @ $2.00 pre-RS and added in the $1.53 are after the Citizen Stash announcement.
I thought that it will find the bottom around $3.65 and I have to admit that this drop was excessive.
Still, I am more positive than ever for this company to perform well next year and beyond.
If I had any extra cash I would be buying these days.
GLTA
STOP PUMPING THIS POS
The total worth of the transaction in Valens shares for Citizen Stash.
CS Q3 nine months revenue was $10.79M CAD so it seems like they will be making north of $14M CAD for the year instead of $12.6.
I made a mistake with the CS revenue gross margin. It is NOT 84%. It is far less than that.
Item 2 – Identity of the Acquiror
2.1 State the name and address of the acquiror.
The Valens Company Inc. (“Valens”). The address of the head office of Valens is 96 Spadina Avenue, Suite 400, Toronto, Ontario M5V 2J6.
2.2 State the date of the transaction or other occurrence that triggered the requirement to file this report and briefly describe the transaction or other occurrence.
Effective November 8, 2021, Valens and Citizen Stash completed a court-approved plan of arrangement under Section 192 of the Canada Business Corporations Act (the "Arrangement"), pursuant to the arrangement agreement dated August 30, 2021 (the “Arrangement Agreement”).
Pursuant to the Arrangement, among other things, Valens acquired all the issued and outstanding Common Shares (including Common Shares issued pursuant to outstanding Citizen Stash restricted share units and in connection with certain financial advisory services rendered) based on an exchange ratio of 0.1620 of a Valens common share (a “Valens Share”) in exchange for each Common Share held.
In addition, Valens “cashed out” all outstanding in-the-money Citizen Stash options for their “in-the- money amount” and paid for the same by the issuance of Valens Shares (based on the same indicative trading prices).
The Arrangement is more particularly described in the information circular of Citizen Stash dated September 28, 2021 (the “Circular”) in connection with a special meeting of the securityholders of Citizen Stash. The Circular, the Arrangement Agreement, and other related documents have been filed on SEDAR and are available under Citizen Stash’s profile at www.sedar.com
Item 3 – Interest in Securities of the Reporting Issuer
3.1 State the designation and number or principal amount of securities acquired or disposed of that triggered the requirement to file the report and the change in the acquiror’s securityholding percentage in the class of securities.
Pursuant to the Arrangement, Valens acquired 106,265,303 Common Shares, representing all of the issued and outstanding Common Shares.
3.4 State the designation and number or principal amount of securities and the acquiror’s securityholding percentage in the class of securities, immediately before and after the transaction or other occurrence that triggered the requirement to file this report.
Immediately before the completion of the Arrangement, Valens did not own or control any Common Shares. Immediately after the completion of the Arrangement, Valens owned 106,265,303 Common Shares, representing all of the issued and outstanding Common Shares.
3.5 State the designation and number or principal amount of securities and the acquiror’s securityholding percentage in the class of securities referred to in Item 3.4 over which
(a) the acquiror, either alone or together with any joint actors, has ownership and control,
Pursuant to the Arrangement, Valens acquired, and following the completion of the Arrangement, Valens now directly has ownership or control of 106,265,303 Common Shares, representing all of the issued and outstanding Common Shares.
Item 4 – Consideration Paid
4.1 State the value, in Canadian dollars, of any consideration paid or received per security and in total.
Pursuant to the Arrangement, former holders of Common Shares received 0.1620 of a Valens Share for each Common Share held. In addition, the outstanding in-the-money Citizen Stash options, were transferred to Citizen Stash for their in-the-money amount, paid in Valens Shares.
Based on the closing price of the Valens Shares on the TSX-V on November 5, 2021 of C$1.76, being the last trading day prior to the completion of the Arrangement, the value of the consideration per Common Share was C$0.285 and the total consideration for the acquisition was C$30,298,363, all payable in Valens Shares.
-----------------------------------------------------------------------------------
So it seems like 0.1620 X 106,265,303 = 17,214,979 Valens shares. So far.
With Valens shares outstanding about 185M.
That's about a 9.3% dilution for an additional 12.6M CAD in annual revenue to the already 93.1M CAD projected for this fiscal year or 13.55% added in annual revenue run rate.
And from the last fins report, CS operates with an 84% gross margin.
Valens should be able to double the output of CS within the first year IMHO.
It seems like a good deal with great contribution overall.
Do you know how many Valens shares were traded for this company ? The total amount.
Just trying to keep track of the shares outstanding.
Thanks.
They said something about CS's SEDAR filings.
The Valens Company scales up and begins to show what it was 'made to do'
Snapshot
The Valens Company closes C$54.3M acquisition of Citizen Stash Cannabis in all-stock deal
The Valens Company receives ‘positive’ buy rating from Stifel following two acquisitions
The Valens Company signs a key deal with Aurora Cannabis while also entering Quebec Market
https://www.proactiveinvestors.com//companies/news/913854/the-valens-company-scales-up-and-begins-to-show-what-it-was-made-to-do-913854.html?SNAPI
Thanks , I see it. It took 6 months to almost double the AUC. A fast growth. Someone posted this ticker on the Stocktwits EQOS board and I got interested in this ticker.
What’s the timeframe for this achievement ?
New 12 months fwd PT average: CAD $3.88 or $3.13USD
https://www.marketbeat.com/stocks/OTCMKTS/VLNCF/price-target/?RegistrationCode=SocialMedia-StockTwits&utm_source=GeneralSocialMedia&utm_medium=Social&utm_campaign=SocialMedia
The Valens Company Announces Entry to Québec Market
Kelowna, B.C., October 18, 2021 – The Valens Company Inc. (TSX: VLNS) (OTCQX: VLNCF) (the “Company,” “The Valens Company” or “Valens”), a leading manufacturer of cannabis products, today announced that it has executed a letter of intent with Société québécoise du cannabis (“SQDC”) for the distribution of its cannabis products into Québec. This marks a significant milestone for Valens entering the third-largest cannabis market in Canada, representing approximately 15% of Canadian cannabis retail sales2 in the country and approximately 22% of the Canadian population.3
“We are pleased to announce the entrance into the Québec marketplace,” said Tyler Robson, Chief Executive Officer, Co-Founder, and Chair of The Valens Company. “This an important milestone for The Valens Company with a national distribution platform that now makes our products accessible to over 95% of the Canadian population. This letter of intent showcases our innovation and consumers should expect new product offerings coming to the Québec marketplace soon. We expect our products to be first available at the beginning of 2022.”
At Valens, it’s Personal.
Governor Newsom Issues Legislative Update 10.6.21
Published: Oct 06, 2021
SACRAMENTO – Governor Gavin Newsom today announced that he has signed the following bills:
AB 45 by Assemblymember Cecilia Aguiar-Curry (D-Winters) – Industrial hemp products.
https://www.gov.ca.gov/2021/10/06/governor-newsom-issues-legislative-update-10-6-21/
https://leginfo.legislature.ca.gov/faces/billTextClient.xhtml?bill_id=202120220AB45
A boost to the Hemp CBD industry and the beginning of of a trend in the US.
I can see $30 in Q1 too with Q3 around $25M and Q4 close to $27.5M.
The revenue numbers should improve going forward and the margins will improve in time with production volume.
I believe that the gross margin for next FY (excluding all the non-related item) should improve to the 55-60% range and should close the year strong.
Nasdaq is good for liquidity but it could be very tricky getting there and once uplisted. And it could easily take longer to uplist. Normally the stocks that uplist are either pumped up to historic highs or run down for many weeks to shake the weak hands and kind of purge and rinse the stock. It all depends on the general sentiment on the stock, sector and industry at the time of the uplisting.
The stock price average plays an important role but I think that the price should correct itself upwards with the next couple of financials reports. So I see Nasdaq as a Spring or Summer event next year. The company doesn't need to rush into this really. It's even better to do that after a couple of good Q reports to go in showing strength to have a good welcome treatment..
The only reason to rush into the Nasdaq or any big board is when you want to be the first in your trade or business model. Or if you are seeking to raise a good amount of cash for expansion. Other than that, good timing should be part of the strategy. If the company has in mind more foreign acquisitions like they are implying lately then they need to get to the Nasdaq soon, now that all the prices are depressed and the market conditions are great for consolidation.
JMHO
Lots of great takeaways in this PR
"The majority of the agreements were signed in the last three weeks, indicative of the significant interest in the capabilities provided by the Valens platform. "
“These agreements, which encompass some of our largest Canadian Licensed Producer partners, represent the vast range of our manufacturing capabilities, reinforcing that we are an ally to our customers and consumers,” said Tyler Robson, Chief Executive Officer, Chair, Co-Founder of The Valens Company."
“Notably, the size of these agreements align with our promise of fewer, bigger, better in terms of relationships and products, ensuring we remain focused on providing the highest shareholder value. Additionally, this marks the largest third-party edible agreement to date for LYF Food Technologies. We are excited to have these partners on board and will continue to focus on adding partners that align with our values.”
-----------------------------------------------
1. Being very selective: Means they know they can keep the ship full and down going forward so any new partner/client needs to have the cash to play with them.
2. A lot of interest in their capabilities is a no brainer & great growth indicator. And the growth will be in two very material and important aspects: Economic growth and also as a company brand, name & platform. If the company performs well with all these contracts and manages to grow and run the platform to it's full capacity in the next couple of years, this will serve as a learning experience for when they need to move south of the border with these services and globally. It's a win-win experience.
3. Being selective when choosing their clients and partners also means that they are not afraid of the market conditions going forward. They see growth ahead and maximum utilize¡ration of their services either buy clients, partners or by themselves.
4. By imposing initial 100% down payments to some shows strength and filters the few operations that they want to work with. This measure also secures a positive cash flow right away and prevents compromising production capabilities and resources with weak players. Again a win -win takeaway. It seems like they see their platform operating to full capacity in the near future .
A great PR over all. All the green signs are there well lit up.
Many great takeaways in the past year or so. The way I see Valens is that they have been a middle man for a few years and that gave them the chance to learn about this industry from the inside without exposing themselves to too much risk. Now they know what they want (and they took) and how to get there. So much so that they managed to reinvent themselves during the pandemic.
I am very prone to LOW capital intensive businesses and that’s what Valens wants in all their branches so I am onboard to stay this time around. They know that their strength is in the platform to add value to the products at low costs. This means great margins when the production volume increase.
Valens owns the science (The Platform) for adding value to the distillates and they are pursuing the global cannabis markets.
This company could become a cannabis powerhouse in a few years. Slowly but surely. A solid business.
A high percentage of the business will produce recurring - like revenue.
This is what I am seeing. They have a lot of room to grow production volumes and efficiencies with all the new businesses acquired.
It will be interesting to see all of these develop in the next 3 years.
I like investing in companies that make sense to me.
Very smart people leading the company. You can tell by the kind of deals they make. To me, all financially sound as far as I can understand them.
Valens owns the SCIENCE. That's the the bridge from the plant to the world. Collecting a toll is in the nature of the business.
They started as a pick and shovel cannabis play. Got to know the market and the players well.
Survived the pandemic and reinvented themselves.
Kept their priorities straight as a low capital intensive and asset light operation.
Very high Gross Margins at the beginning and I am sure they will go back to that in the future.
Now, they are getting involved in all the key and faster growing segments of the market ecosystem.
Going global in different ways.
When all of these factors are added up, the risks are reduced enormously going forward.
And then it's trading at bottom prices.
It's a special situation right now. It's hard NOT to get involved if you plan to hold long and see it through.
I always size the potential for the longer term.
I forgot Japan with the Green Roads latest partnership.
Bought back in yesterday and today all morning.
I like the vision of this company. I always did. Holding Long as I see continuous growth ahead.
https://www.proactiveinvestors.com/companies/news/913854/the-valens-company-scales-up-and-begins-to-show-what-it-was--made-to-do--913854.html
Stifel GMP has issued a "positive" buy rating and target price of $5.75 on The Valens Company (TSX:VLNS, OTCQX:VLNCF) a day after the cannabis manufacturer announced the completion of its acquisition of Verse Cannabis.
The deal for the Canadian cannabis retailer will see Valens take ownership of all of the Verse intellectual property. Just a few weeks earlier Valens also reported that it was purchasing Citizen Stash Cannabis Corp, a Canadian premium craft cannabis company, in an all-stock transaction valued at about C$54.3 million. Both deals were cited in the analyst coverage from Stifel.
“With these two transactions, VLNS captures the Verse royalty payment, reduces execution risk and provides for greater control over brand positioning at both extreme price segments in the industry, potentially balancing margin profiles,” Stifel analysts said in their note.
https://www.proactiveinvestors.com/companies/news/959347/the-valens-company-receives-positive-buy-rating-from-stifel-following-two-acquisitions-959347.html
The Valens Company (TSX:VLNS, OTCQX:VLNCF) Inc. has announced an exclusive partnership with Epsilon Healthcare Limited, a diversified global healthcare and pharmaceuticals company, for access to Epsilon's Good Manufacturing Practices (GMP) facility in Australia for manufacturing products.
In a statement, Valens said the partnership furthers its international expansion to GMP's markets in Latin America, Europe, UK, and the Asia-Pacific regions.
Products will be distributed through Valens' Australian distribution partner, Cannvalate PTY Ltd, and to date, will be the largest quantity of products provided to Cannvalate for distribution.
https://www.proactiveinvestors.com/companies/news/959768/the-valens-company-expands-international-footprint-to-asia-pacific-region-via-exclusive-australian-partnership-959768.html
Population of: (In Millions)
USA....................334.30
UK........................68.44
Canada.................38.25
Australia...............26.04
New Zeland...........4.86
Dominican Rep.....11.02
Costa Rica.............5.17
Panama.................4.40
------------------------------------------
Increased global exposure, achieving one of the Company's major strategic initiatives for fiscal 2021. Valens' entry into the US market is anticipated to open global distribution opportunities, with Green Roads and Valens-manufactured products collectively already sold in over 11 countries in several formats. The Company is currently engaged in late-stage discussions regarding various international distribution opportunities in Latin America, Asia-Pacific, and Europe.
https://www.prnewswire.com/news-releases/the-valens-company-completes-acquisition-of-leading-us-cbd-company-green-roads-301316091.html
LFMD Institutional Holdings
Ownership Summary
Label Value
Institutional Ownership 18.04 % (2.7% pre- Culper hit piece)
Total Shares Outstanding (millions) 26
Total Value of Holdings (millions) $36
Active Positions
ACTIVE POSITIONS HOLDERS SHARES
Increased Positions 44 4,373,540
Decreased Positions 4 524,876
Held Positions 1 177,201
Total Institutional Shares 49 4,721,215
https://www.nasdaq.com/market-activity/stocks/lfmd/institutional-holdings
I also see this as a positive in he credibility front. And institutions are not waiting on the sidelines any more. Very strategically filed on the same day of the Q report for an extra bang.
Also, with all that after hour volume, the price never dropped below the closing price. The after hour trading remained bullish the whole time.
The volume last Friday almost doubled the record volume of 7.43M shares form a month ago on April 16. Hims is depressed and trading @ 11.4X ttm sales. The stock should recover a couple of P/S full points LFMD, when short hit-piece corrected, is also depressed and trading @ 4.4X ttm sales. HIMS has an estimated 2021 growth rate of 35-40%. LFMD has an estimated 2021 growth rate of 155%.
And further dilution should be minimum according to the Mgmt. plans.
I have been reading all weekend everything related to the company's financial performance and it's becoming more evident that the LFMD growth story is very real. I think that most people that did some research over the weekend will agree with me.
The daily volume will remain substantial once the volatility subsides. 0.75 to 1.0M shares minimum per day, my estimate.
Institutional investment into LFMD has increased by 400% (5X) at least in the past month.
Any financial facility planned should become a lot easier with the latest & great Q report/guidance.
Finally, the law suit against Culper should reduce the short trading action. The recent financial performance and projections are very strong and makes it very risky for the shorts anyways.
I believe that tomorrow will be another strong bullish day. And this is JMHO.
GLTA tomorrow and the rest of the week.